U.S. markets closed
  • S&P 500

    4,140.06
    -5.13 (-0.12%)
     
  • Dow 30

    32,832.54
    +29.07 (+0.09%)
     
  • Nasdaq

    12,644.46
    -13.10 (-0.10%)
     
  • Russell 2000

    1,941.21
    +19.38 (+1.01%)
     
  • Crude Oil

    90.49
    +1.48 (+1.66%)
     
  • Gold

    1,786.40
    +13.50 (+0.76%)
     
  • Silver

    20.67
    +0.83 (+4.17%)
     
  • EUR/USD

    1.0196
    +0.0008 (+0.08%)
     
  • 10-Yr Bond

    2.7650
    -0.0750 (-2.64%)
     
  • GBP/USD

    1.2083
    +0.0012 (+0.10%)
     
  • USD/JPY

    134.9710
    +0.0010 (+0.00%)
     
  • BTC-USD

    23,941.79
    +590.96 (+2.53%)
     
  • CMC Crypto 200

    559.83
    +16.96 (+3.12%)
     
  • FTSE 100

    7,482.37
    +42.63 (+0.57%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Top Stock Picks for Week of August 1, 2022

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Illumina Inc. ILMN is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function.llumina exited first-quarter 2022 with better-than-expected earnings and revenues. The robust year-over-year improvement in Core Illumina businesses looks encouraging. Revenue contributions from the newly-formed GRAIL business, primarily from Galleri test fees, bode well. NovaSeq consumable and instrument shipments reached new highs during the quarter as the company witnessed robust demand for NextSeq 1000, 2000 from new customers. The company also saw significant growth in the installed base and a record backlog, instilling optimism. Apart from North America, Illumina markets and distributes its products directly to customers in Europe, Latin America, and the Asia-Pacific region (APAC) either through its direct selling force or through distributors that specialize in life science products. We are optimistic about Illumina’s expansion strategy through the enhancement of its portfolio of sequencing products through new purchases and the development of strategic partnerships with therapeutics and diagnostic services providers.

Dollar General Corporation DG is one of the largest discount retailers in the United States.Dollar General remains a compelling growth story in the retail space. Thanks to its value-creating initiatives, defensive product mix and real estate growth strategy, the company has the capabilities to gain market share. Its commitment to better pricing, private label offerings, effective inventory management and merchandise initiative should drive sales. We also remain encouraged by the company’s host of initiatives such as DG Fresh, Fast Track, non-consumables, digitization and private fleet that should yield same-store sales growth and margin expansion. Markedly, we expect same-store sales to increase 3.5% and 3% in fiscal 2022 and 2023, respectively. Clearly, there are reasons to believe that this discount retailer has the potential to scale higher, driven by solid prospects, brand recognition and a positive earnings outlook. In spite of supply chain bottlenecks and heightened inflation, Dollar General reported stronger-than-anticipated first-quarter fiscal 2022 results.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Dollar General Corporation (DG) : Free Stock Analysis Report
 
Illumina, Inc. (ILMN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research